General information
GEMoaB Monoclonals GmbH
Tatzberg 47
01307 Dresden, Saxony
Germany
Contact person: Michael Pehl, CEO
Company main phone: +49 (351) 44664500
Website: www.gemoab.com
Year founded: | 2011
|
Source of foundation: | Independent foundation |
Corporate description / mission:
GEMoaB GmbH is a privately-owned, limited liability biopharmaceutical company based in Dresden, Germany. The company discovers, develops, manufactures, and commercializes next-generation immunotherapies for the treatment of cancer patients with a high unmet medical need.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Antibodies
- Immunotherapy
- Other
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Customer segments: |
- Other
- Hospitals
- Large biotech & big pharma
- Physicians / doctors
|
Summary Products / Services / Technologies
Description of products:
GEM333
GEM3PSCA
UniCAR-T-PSMA
UniCAR-T 3, etc.
Technology used:
UniCAR/RevCAR Platforms
ATAC Platform